Cargando…

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated in the Nordic Lymphoma Group trials, MCL2 or M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eskelund, Christian Winther, Dimopoulos, Kostas, Kolstad, Arne, Glimelius, Ingrid, Räty, Riikka, Gjerdrum, Lise Mette Rahbek, Sonnevi, Kristina, Josefsson, Pär, Nilsson-Ehle, Herman, Bentzen, Hans H. N., Fagerli, Unn Merete, Kuittinen, Outi, Haaber, Jacob, Niemann, Carsten Utoft, Pedersen, Lone Bredo, Larsen, Maria Torp, Geisler, Christian Hartmann, Hutchings, Martin, Jerkeman, Mats, Grønbæk, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755521/ https://www.ncbi.nlm.nih.gov/pubmed/33364550 http://dx.doi.org/10.1097/HS9.0000000000000510

Ejemplares similares

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
por: Lokhande, Lavanya, et al.
Publicado: (2021)

P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
por: Husby, S., et al.
Publicado: (2022)

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
por: Freiburghaus, Catja, et al.
Publicado: (2018)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Outcomes Following ACL and Grade III MCL Injuries: Is there a Role for MCL Repair?
por: Westermann, Robert W., et al.
Publicado: (2017)

PorthoMCL: Parallel orthology prediction using MCL for the realm of massive genome availability
por: Tabari, Ehsan, et al.
Publicado: (2017)

Which Fibers of the Medial Collateral Ligament (MCL) Should Be Released in the Pie Crust Technique Applied During Knee Arthroscopy: Superficial MCL or Deep MCL?
por: Arıcan, Gökhun, et al.
Publicado: (2021)

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021)

Mcl-1 Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011)

Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability
por: Ah-Cann, Casey, et al.
Publicado: (2016)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability
por: Tantawy, Shady I., et al.
Publicado: (2023)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2019)

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
por: Lokhande, Lavanya, et al.
Publicado: (2020)

Mcl-1 and tumor cell persistence
por: Pfannenstiel, Lukas W., et al.
Publicado: (2014)

MCL-1 inhibition in cancer treatment
por: Xiang, Weiguo, et al.
Publicado: (2018)

MCL1 as putative target in pancreatoblastoma
por: Reissig, Timm M., et al.
Publicado: (2022)

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines
por: Eichhorn, J M, et al.
Publicado: (2013)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

Regulation of Neutrophil Survival/Apoptosis by Mcl-1
por: Milot, Eric, et al.
Publicado: (2011)

Allosteric Inhibition of Anti-Apoptotic MCL-1
por: Lee, Susan, et al.
Publicado: (2016)

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers()()
por: Wei, Dongping, et al.
Publicado: (2015)

MCL-CAw: a refinement of MCL for detecting yeast complexes from weighted PPI networks by incorporating core-attachment structure
por: Srihari, Sriganesh, et al.
Publicado: (2010)

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
por: Lee, Erinna F., et al.
Publicado: (2008)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

A simple molecular design towards the conversion of a MCL backbone to a multifunctional emitter exhibiting polymorphism, AIE, TADF and MCL
por: Huang, Bin, et al.
Publicado: (2022)

MCL Reconstruction Using a Flat Tendon Graft for Anteromedial and Posteromedial Instability
por: Abermann, Elisabeth, et al.
Publicado: (2022)

Mcl-1 is a key regulator of the ovarian reserve
por: Omari, S, et al.
Publicado: (2015)

Surgeon-Major A.E. McL. Ross
Publicado: (1885)

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021)

The multiple mechanisms of MCL1 in the regulation of cell fate
por: Widden, Hayley, et al.
Publicado: (2021)

Targeting MCL-1 in cancer: current status and perspectives
por: Wang, Haolan, et al.
Publicado: (2021)

Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells
por: Pervin, S, et al.
Publicado: (2011)

Cytokine-dependent and cytokine-independent roles for Mcl-1: genetic evidence for multiple mechanisms by which Mcl-1 promotes survival in primary T lymphocytes
por: Dunkle, A, et al.
Publicado: (2011)

Traumatic Great Toe Mcl Avulsion in Professional Athlete Treated Surgically with Mcl Repair with Suture Tape Augmentation Allowing Rapid Return to Sport
por: Epstein, Caroline, et al.
Publicado: (2022)

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
por: Nikkarinen, Anna, et al.
Publicado: (2023)

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
por: Santer, Frédéric R., et al.
Publicado: (2015)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h8vpdob4hgcppulquhf77uoguu